A phase II study for metabolic in vivo response monitoring with sequential (18)FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial

BACKGROUND: The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Anne Katrin, von Gall, Carl, Abel, Ulrich, Delorme, Stefan, Kloor, Matthias, Ose, Jennifer, Weber, Tim Frederik, Stange, Annika, Haag, Georg Martin, Haberkorn, Uwe, Lordick, Florian, Jäger, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366909/
https://www.ncbi.nlm.nih.gov/pubmed/22439666
http://dx.doi.org/10.1186/1471-2407-12-108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366909/
https://www.ncbi.nlm.nih.gov/pubmed/22439666
http://dx.doi.org/10.1186/1471-2407-12-108

Ejemplares similares